Alexandria

Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Long QT Syndrome (LQTS) is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life threatening ventricular arrhythmias. Click below to learn more about our programs.

Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.

IgGenix, Inc, a biotechnology company, develops an antibody therapeutics platform for the treatment of food and non-food allergies, and other severe allergic conditions. It isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and prevent the allergic cascade. The company captures and analyzes very rare human B cells that express allergen-binding antibodies, and engineers them with immune modulating activities derived from the IgG antibody class to suppress allergic reactions. The company was incorporated in 2019 and is based in South San Francisco, California.

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

TwinStrand Biosciences, Inc. develops and commercializes Duplex Sequencing that allows levels of accuracy and sensitivity. The company’s Duplex Sequencing improves the accuracy of DNA sequencing by various folds and allows detection of mutations that are invisible by other approaches. Its technology has applications in a range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company was incorporated in 2015 and is headquartered in Bellevue, Washington.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

Ambys Medicines is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.

Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.

Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.

Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

IpiNovyx Bio is a biopharmaceutical company developing a platform of best-in-class immunoproteasome modulating therapeutics to transform the treatment of autoimmune and inflammatory diseases.

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Terray Therapeutics, Inc. operates as a biotechnology company. The company develops treatments for intractable cause of human diseases. It engages in development of a screening platform for drug discovery and Platinum Technology, which is working on an electrode-like product for deep brain stimulation. The company was founded in 2018 and is based in Pasadena, California.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. The company was founded in 2020 by Chad Brommer and is headquartered in Raleigh, North Carolina, United States.

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Eclipse Bioinnovations is an RNA Next-Generation-Sequencing company founded in 2017 based on technology developed in Professor Gene Yeo’s laboratory at UC San Diego. Their mission is to use their first-in-class Eclipse-Seq RNA NGS platform technologies to accelerate the creation and development of truly safe and effective RNA medicines. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s eCLIP is offered as a service and kit for biopharma companies and academic researchers, and can be customized for different RNAs such as siRNA or miRNA.

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.

Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Neurona Therapeutics Inc. develops cell-based therapies for the treatment of neurological disorders. The company develop therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system. The company was incorporated in 2008 and is based in South San Francisco, California.

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,

Invaio Sciences, Inc. is a Flagship Pioneering Company startup in Cambridge. They are at the forefront of developing novel technologies based on groundbreaking science with an intent to positively impact their planet by enabling the application of breakthrough solutions in agriculture, human health, animal nutrition and animal health.

Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

Boragen develops synthetic chemistry platforms designed to produce next-generation fungicides. The platform supports sustainable farming methods by creating a compound that decreases the probability of fungicide resistance and reduces the amount of chemical applied while maintaining performance and efficacy. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health, and human health. Founded in 2015, Boragen is based in Durham, North Carolina.

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.

Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Shenandoah Growers is a grower, packer, and shipper of fresh organic culinary herbs. The company provides a 365-day supply of fresh, organic herbs to grocery stores, so millions of consumers can now eat locally all year. Their products are healthy, delicious, and aimed at making the world a lot more flavorful.

TwinStrand Biosciences, Inc. develops and commercializes Duplex Sequencing that allows levels of accuracy and sensitivity. The company’s Duplex Sequencing improves the accuracy of DNA sequencing by various folds and allows detection of mutations that are invisible by other approaches. Its technology has applications in a range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company was incorporated in 2015 and is headquartered in Bellevue, Washington.

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.

Crop Enhancement LLC, an early stage specialty materials company, develops anchoring and controlled-release formulation technologies for agricultural chemicals. The company’s formulation technologies enable release of chemical agents, such as pesticides, herbicides, and fertilizers into target microenvironments. Crop Enhancement LLC was founded in 2011 and is based in San Jose, California.

Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts.

GeneCentric Diagnostics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Molecular Assemblies, Inc. develops an enzymatic DNA synthesis technology for DNA-based products. Its technology enables the reading and writing of DNA for various industries. The company serves life sciences, industrial, information storage, nanotechnology, and DNA electronics markets. Molecular Assemblies, Inc. was founded in 2013 and is based in San Diego, California.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.

Deep Genomics Inc., an artificial intelligence (AI) therapeutics company, develops individualized genetic medicines by creating AI systems that are used to accelerate various steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment, and innovative trial design. It develops and markets therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company develops oligonucleotide therapies that target the genetic determinants of disease at the level of RNA or DNA. Deep Genomics Inc. was founded in 2014 and is based in Toronto, Canada.

Early stage biotechnology start-up developing next generation cytokine therapeutics

IgGenix, Inc, a biotechnology company, develops an antibody therapeutics platform for the treatment of food and non-food allergies, and other severe allergic conditions. It isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and prevent the allergic cascade. The company captures and analyzes very rare human B cells that express allergen-binding antibodies, and engineers them with immune modulating activities derived from the IgG antibody class to suppress allergic reactions. The company was incorporated in 2019 and is based in South San Francisco, California.

Ozette is a life sciences data startup company that develops an artificial intelligence-enabled immune monitoring platform. It empowers scientists to quickly extract reliable insights from single-cell data across instruments, experiments, and disease states, with a focus on cancer patients. The data can be used by doctors to diagnose and prescribe medication with greater accuracy. In 2020, co-founders Raphael Gottardo, Greg Finak, Ali Ansary, and Evan Greene headquartered the life science company in Seattle, Washington.

GNS Healthcare is a big data analytics company that focuses on discovering what works in the healthcare industry and for whom. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment, and cost challenges. It was founded in 2000 and headquartered in Cambridge, Massachusetts.

Tavros Therapeutics is an emerging biotechnology company that discovers and develops therapies for cancer. The company was founded in 2019 and based in Durham, North Carolina.

Senda Biosciences is pioneering the field of Intersystems Biology to create novel treatments for human disease. Intersystems Biology focuses on how molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. Senda's Intersytems Biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this "pharmacy within us" with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease.

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.

Inari Agriculture, Inc. develops customized seeds to grow crop using CRISPR gene editing technology. The technology helps crops grow in local conditions such as humidity, temperatures, and soil types. The company uses the technology on seeds such as wheat, soya bean, and corn. Inari Agriculture, Inc. was formerly known as VL40, Inc. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

Avalo is a biotech company generating crop resilience through gene discovery and control for a healthier and fuller world. The company uses interpretable machine learning to identify genes in plants at a much faster pace to help develop better crops.

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Humacyte, Inc., a medical research, discovery, and development company, focuses on developing and commercializing a proprietary technology based on human tissue-based products for application in regenerative medicine and vascular surgery. It designs acellular extracellular matrices, which are formed in vitro from banked vascular smooth muscle cells and decellularized to eliminate the risk of rejection; and used as tissue-engineered grafts for patients in need of vascular repair or replacement. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing.

SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.

Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs.

Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.

Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Molecular Assemblies, Inc. develops an enzymatic DNA synthesis technology for DNA-based products. Its technology enables the reading and writing of DNA for various industries. The company serves life sciences, industrial, information storage, nanotechnology, and DNA electronics markets. Molecular Assemblies, Inc. was founded in 2013 and is based in San Diego, California.

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

QurAlis Corporation discovers and develops therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases. The company’s pipeline includes treatments for subtypes of ALS, such as a drug to restore a dysfunctional cellular waste clearance system that poisons neurons; a therapy to treat overactive neurons and prevents resulting cell death; and an approach to remove toxic proteins. The company was incorporated in 2016 and is based in Cambridge, Massachusetts. QurAlis Corporation operates as a subsidiary of Q-State Biosciences, Inc.

Cibus’ breeding technology works without integrating foreign genetic material, thus the resulting organisms are non-transgenic (non-GM). The Company has developed and patented advanced breeding technologies that enable precise, stable, predictable changes to be made in plants and other organisms without integrating foreign genetic material. Cibus has launched its first crop, SU Canola™, in North America and expects to develop non-transgenic traits in every major crop.

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits. It was founded in 2018 and headquartered in Seattle, Washington.

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Cardea Bio Inc., a biotech company, develops, manufactures, and delivers commercial graphene-based digital biosensor hardware, software, and molecular infrastructure. The company focuses on creating products and applications that enable precision healthcare by improving diagnostic ease, speed, and cost. Its insight biosensors use the conductive and biocompatible nanomaterial graphene to convert biomolecules into digital elements enabling biology to connect directly to digital networks and creating access to biological data. The company was founded in 2013 and is headquartered in San Diego, California.

Immusoft Corporation operates as a biotechnology company that develops an autologous cell therapy platform for treating various human diseases through its Immune System Programming (ISP) technology. The company develops protein therapeutics using a patient's cells. Its technology enables the in vivo delivery of gene-encoded medicines (biologics) by re-programming the patient’s cells to replace missing or defective enzymes and proteins. The company was founded in 2009 and is based in Seattle, Washington.

EpiBiome is a venture-backed precision microbiome engineering company tackling the challenge of antibiotic resistance by developing alternatives to small-molecule antibiotics for use in healthcare, veterinary and agriculture industries. Antibiotic-resistant bacteria surpass nuclear warfare, climate change, and terrorism as the biggest challenge facing humanity today. The pipeline of new antibiotics has slowed to a trickle, while the emergence of multi-drug resistant bacteria is on an unprecedented trajectory. These bacteria threaten to reverse more than 100 years of medical progress by making all but the most necessary surgical procedures too risky due to the threat of post-operative infection.

Cydan II, Inc. is a drug accelerator which develops therapies for rare genetic diseases. The company evaluates products for treating rare genetic diseases and further development by biotechnology companies. The company conducts de-risking studies on diseases and disorders with a genetic etiology. It develops therapies for Niemann-Pick Disease Type C and IMR-687, a treatment for sickle cell disease. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Redpin Therapeutics, Inc., gene therapy company, develops a chemo genetics platform for targeted cell therapies that address intractable diseases of the nervous system. It discovers and develops an ion channel-based chemo genetics platform that enables targeted cell activation/inhibition controlled by low doses of the anti-smoking drug Varenicline. Redpin Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Biological Dynamics is an early-stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Their vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs. It was founded in 2008 and is headquartered in San Diego, California.

ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.

Trucode Gene Repair, Inc. operates a triplex gene editing platform for curing genetic diseases. It focuses on sickle cell disease and cystic fibrosis. The company develops a pipeline of novel, proprietary therapeutic products for high-penetrance disease genes to alleviate and cure genetic disorders in patients. The company was founded in 2016 and is based in South San Francisco, California.

Inari Agriculture, Inc. develops customized seeds to grow crop using CRISPR gene editing technology. The technology helps crops grow in local conditions such as humidity, temperatures, and soil types. The company uses the technology on seeds such as wheat, soya bean, and corn. Inari Agriculture, Inc. was formerly known as VL40, Inc. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.

Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. It uses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical need. Applied Therapeutics conducts its business in the United States.

MouSensor, Inc., a biotechnology company, develops a platform to digitize the sense of smell. It engineers super sniffer mice to build a live nose-on-a-chip to detect, discover, and digitize various smells on the planet ranging from the fragrances in a perfumer's palette to odors associated with diseases, such as Parkinson's disease. MouSensor, Inc. was founded in 2016 and is based in New York, New York.

Calimmune, Inc., a clinical-stage human immunodeficiency virus (HIV) gene medicines company, develops cell-based therapies for HIV. The company offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. It also focuses on developing products to address the needs of various types of individuals at different states of HIV infection and with different levels of treatment experience. The company was founded in 2000 and is based in Tuscon, Arizona. As of August 31, 2017, Calimmune, Inc. operates as a subsidiary of CSL Behring LLC.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Petra Pharma Corporation, a pharmaceutical company, discovers and develops therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and other serious diseases. It focuses on novel enzyme targets that play a central role in various important cellular processes, including cell division, growth, trafficking, and signaling. The company was incorporated in 2015 and is based in New York, New York.

MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.

Triplet Therapeutics, Inc. develops therapeutics and treatments for triplet disorders. It develops treatment for repeat expansion disorders, including Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Triplet Therapeutics, Inc. was formerly known as rzna, Inc. The company was founded in 2018 and is based in Cambridge, Massachusetts.

LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.

Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Think Brilliant Media Studios specializes in high performance web development and custom media solutions across multiple platforms.

WellDoc is developing the next generation of technology solutions to support chronic disease management. Its mission is to improve the lives of people with chronic diseases they fulfill their mission by integrating clinical, behavioral, and motivational applications with everyday technologies, like the internet and cell phone, to engage patients and healthcare providers in ways that dramatically improve outcomes and significantly reduce healthcare costs. It was founded in 2005 and headquartered in Columbia, Maryland.

Faze Medicines, a pharmaceutical company, develops interventions against driver of disease pathology. It develops small molecule drugs for initial therapeutic focus areas, such as amyotrophic lateral sclerosis and myotonic dystrophy type 1. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Molecular Assemblies, Inc. develops an enzymatic DNA synthesis technology for DNA-based products. Its technology enables the reading and writing of DNA for various industries. The company serves life sciences, industrial, information storage, nanotechnology, and DNA electronics markets. Molecular Assemblies, Inc. was founded in 2013 and is based in San Diego, California.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Ubiq is a technology company that has simplified the complex and messy world of encryption through a set of APIs, that are simple enough for any developer to use, yet scalable and extensible enough to encrypt data effortlessly across diverse applications and programming languages, cloud environments, and storage types. By enabling developers to quickly integrate encryption into their applications, Ubiq is empowering innovators around the world to efficiently build more secure products and experiences.

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. It uses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical need. Applied Therapeutics conducts its business in the United States.

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.

Genetron Health is a world-leading expert in precision medicine.They are committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomic data to assist medical experts and research scientists. Additionally, they provide cancer patients and high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.In just three years, Genetron Health has built global genomics sequencing and bioinformatics platforms, established two research and development centers in both North Carolina, U.S., and Beijing, China, and set up clinical laboratories in Beijing, Shanghai, Hangzhou and Chongqing of over 10,000 square meters.In the future, Genetron Health will spread its sales network throughout China with professional marketing, product management, medical experts and scientific research teams, and will provide service for Chinese and global cancer patients with its strong foundation in cancer genomics and efficient clinical translation.

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology, biophysics and chemistry, enabling pharmaceutical companies to solve and design therapies against complex diseases like cancer and others.

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Cydan II, Inc. is a drug accelerator which develops therapies for rare genetic diseases. The company evaluates products for treating rare genetic diseases and further development by biotechnology companies. The company conducts de-risking studies on diseases and disorders with a genetic etiology. It develops therapies for Niemann-Pick Disease Type C and IMR-687, a treatment for sickle cell disease. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Seres Health is a clinical-stage therapeutics company focused on discovering and developing drugs to treat diseases of the microbiome. The biology of the microbiome is driven by ecologies—the functional collections of various organisms—which are central to health and disease. Seres is developing Ecobiotic™ therapeutics to treat diseases that have an underlying microbiome biology. Our first clinical program is in the treatment of Clostridium difficile infection.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.

Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Novome Biotechnologies, Inc. engineers and develops bacteria from the human gut to treat diseases. Its platform enables controllable engraftment of genetically engineered microbial medicines in the gut for sustained therapies. The company’s synthetic biology tools allow to plug into ecosystem and deliver precise activities to treat chronic diseases. Novome Biotechnologies, Inc. was incorporated in 2015 and is based in South San Francisco, California.

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.

Vesigen, Inc. develops therapeutic products directed to intracellular targets using extracellular vesicle delivery technology. The company designs, discovers, and develops medicines that target intracellular delivery, cell membranes, and degradative systems barriers. Its ARMMs technology enables translation of new modalities, such as RNAs and gene-editing complexes into novel treatments for multiple diseases. Vesigen, Inc. was incorporated in 2020 and is based in Cambridge, Massachusetts.

Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

Adaptive Phage Therapeutics, Inc. offers therapeutic solutions for the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company offers PhageBank, a large and dynamically growing collection of bacteriophages or phages (viruses that attack specific targeted bacteria) and a rapid system for matching phage to patient-specific bacterial infections. The company was founded in 2016 and is headquartered in Gaithersburg, Maryland.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology, biophysics and chemistry, enabling pharmaceutical companies to solve and design therapies against complex diseases like cancer and others.

Kinestral Technologies, Inc. manufactures smart-tinting glass for commercial and residential purposes. The company's products include Halio, smart-tinting glass supported by Halio software application that can integrate with smart homes and automation systems; Halio Tint Selector, a wireless device that enables local control of a pre-selected window or group of windows; Halio Cloud, an application program interface to integrate window operations with building automation systems. The company has strategic alliance with Asahi Glass Co., Ltd. The company was incorporated in 2010 and is based in Hayward, California with a location in Salt Lake City, Utah.

We make genomics affordable and accessible through a cost-effective low-coverage whole genome sequencing technology

Celsius Therapeutics, Inc. develops and researches drugs. The company publishes researches topics, such as single-cell genomic analysis to develop life-changing medicines. Celsius Therapeutics, Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

GreenLight Biosciences, Inc., a biotechnology company, develops RNA-based solutions for agriculture and pharmaceutical applications. The company provides technology for the biological conversion of renewable substrates to valuable products. It offers Unconstrained Metabolism, a technology platform that delivers solutions for the production of chemicals and fuels from renewable resources. It also engages in developing mRNA-based vaccine candidates to potentially prevent individuals from contracting SARS-CoV-2. The company also provides research and analysis services. GreenLight Biosciences, Inc. was incorporated in 2008 and is based in Medford, Massachusetts. It has an additional location in North Carolina.

Immunitas Therapeutics, Inc. develops targeted therapeutic for patients with cancer using single cell analyses. It employs a single cell sequencing platform to dissect the biology of immune cells in human tumors and develop key biomarkers. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.

Jasper Therapeutics, Inc., a biotechnology company, develops therapeutic agents for hematopoietic stem cell transplants and gene therapies. It offers JSP191, a humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, which binds to human CD117, a receptor for stem cell factor that is expressed on the surface of hematopoietic stem and progenitor cells. Jasper Therapeutics, Inc. was incorporated in 2018 and is based in Menlo Park, California.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Crop Enhancement LLC, an early stage specialty materials company, develops anchoring and controlled-release formulation technologies for agricultural chemicals. The company’s formulation technologies enable release of chemical agents, such as pesticides, herbicides, and fertilizers into target microenvironments. Crop Enhancement LLC was founded in 2011 and is based in San Jose, California.